COSCIENS Biopharma Inc. (CSCIF) Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets

COSCIENS Biopharma Inc. Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets

COSCIENS Biopharma Inc. (CSCIF) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $27.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-09.

Discontinued › Expense Statement › Operating Expenses

ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2023-11-09

• COSCIENS Biopharma Inc. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2023-09-30 was $27.00K, a 37.21% decline year-over-year.
• COSCIENS Biopharma Inc. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2023-06-30 was $22.00K, a 33.33% decline year-over-year.
• COSCIENS Biopharma Inc. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2022-09-30 was $43.00K.
• COSCIENS Biopharma Inc. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2022-06-30 was $33.00K.